ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
BBS5 as a robust prognostic biomarker in esophageal squamous cell carcinoma: validation in two independent cohorts.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEsophageal squamous cell carcinoma (ESCC) remains a highly lethal malignancy, and reliable biomarkers for predicting metastasis and prognosis are urgently needed. Through comprehensive transcriptomic profiling, we identified Bardet-Biedl syndrome 5 (BBS5) as a potential biomarker of clinical significance.
methodsTranscriptome analysis was performed on surgical specimens from eight ESCC patients with distant metastatic recurrence (discovery cohort, n = 8). BBS5 mRNA expression was quantified by Reverse Transcription Quantitative PCR (RT-qPCR) across 18 ESCC cell lines, and siRNA-mediated knockdown was conducted in two independent high-expressing lines (KYSE1260 and KYSE590) to assess proliferation in both cell lines and migration and invasion in KYSE1260. In 266 patients who underwent curative esophagectomy, BBS5 mRNA levels were measured by RT-qPCR and correlated with clinicopathological features and survival outcomes. Among these, 98 cases additionally underwent immunohistochemical (IHC) assessment of BBS5 protein expression. A second (independent) cohort of 175 ESCC patients was further analyzed using tissue microarray (TMA)-based IHC to validate prognostic relevance.
resultsBBS5 knockdown significantly inhibited proliferation of the BBS5-high ESCC cell lines KYSE1260 and KYSE590, markedly suppressed invasion in KYSE1260 and reduced the migratory capacity of KYSE1260. Tumors exhibited significantly higher BBS5 mRNA expression than adjacent normal tissues. High BBS5 expression was associated with significantly shorter overall survival (P = 0.025), and multivariate analysis identified BBS5 expression as an independent predictor of overall and disease-free survival. IHC analysis confirmed the association between high BBS5 expression and poor prognosis, which was further validated in the second (independent) TMA cohort, in which high BBS5 protein expression independently predicted both overall and disease-free survival.
conclusionsBBS5 promotes ESCC cell proliferation, migration and invasion and serves as a robust prognostic indicator in two independent patient cohorts, highlighting its potential utility as a clinically relevant biomarker.
Indexed as
Identifiers
42611129What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.